Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$197.23 USD

197.23
1,588,572

-0.32 (-0.16%)

Updated Aug 26, 2024 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

What's in Store for Cardinal Health (CAH) in Q4 Earnings?

by Zacks Equity Research

Cardinal Health (CAH) is likely to witness solid growth in the core Pharmaceutical segment in Q4 results. However, lackluster performance in the Cordis unit is likely to mar prospects.

    Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?

    by Zacks Equity Research

    Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.

      Sweta Killa headshot

      Healthcare ETFs to Buy on Solid Q2 Earnings Expectations

      by Sweta Killa

      With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 9.1% in the second quarter, suggesting continued outperformance for healthcare ETFs.

        Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?

        by Zacks Equity Research

        Bristol-Myers (BMY) is scheduled to report second-quarter earnings on Jul 26.

          Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?

          by Zacks Equity Research

          Gilead (GILD) is likely to beat expectations in the second quarter propelled by the momentum in the HIV franchise.

            Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

            by Zacks Equity Research

            J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

              Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

              by Zacks Equity Research

              On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance

                Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?

                by Zacks Equity Research

                Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                  AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.

                  by Zacks Equity Research

                  AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.

                    J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales

                    by Zacks Equity Research

                    J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.

                      Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?

                      by Zacks Equity Research

                      The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2

                        Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

                        by Zacks Equity Research

                        Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

                          AbbVie's Imbruvica Fails in Phase III Blood Cancer Study

                          by Zacks Equity Research

                          AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.

                            J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?

                            by Zacks Equity Research

                            The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2.

                              The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie

                              by Zacks Equity Research

                              The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie

                                Tirthankar Chakraborty headshot

                                Celebrate Trump's 2nd Year in Office With These 5 Winners

                                by Tirthankar Chakraborty

                                There's always a 67% chance that the U.S. stock market will scale north during the second year of presidential terms.

                                  Madhu Goel headshot

                                  3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July

                                  by Madhu Goel

                                  We take a look at the three large cap pharma stocks that might be best bargains for the month of July.

                                    Bristol-Myers' Sprycel Gets EC Approval for Label Expansion

                                    by Zacks Equity Research

                                    Bristol-Myers (BMY) receives EC approval for the label expansion of Sprycel for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in patients aged one to 18 years.

                                      Here's Why AbbVie Stock is Good for Your Portfolio's Health

                                      by Zacks Equity Research

                                      Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.

                                        Is Pfizer's Price Hike an Effect of Drug Policy on Sector?

                                        by Zacks Equity Research

                                        Pfizer (PFE) reportedly raises prices of almost 100 drugs. The new drug policy has a soft stance with no provisions for direct negotiation by Medicare and resorts to competition for restricting price.

                                          AstraZeneca's Two New Cancer Drugs Get Approval in Japan

                                          by Zacks Equity Research

                                          AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.

                                            Sweta Killa headshot

                                            5 Great Dividend Growth Stocks to Counter Volatility

                                            by Sweta Killa

                                            Volatility and uncertainty in the stock market has raised the appeal for dividend growth stocks. Here are five picks.

                                              Vertex's Shares Rally as a Rival's CF Candidate Disappoints

                                              by Zacks Equity Research

                                              Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.

                                                Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion

                                                by Zacks Equity Research

                                                Gilead (GILD) obtains positive opinion from the CHMP for its MAA for CAR T therapy, axicabtagene ciloleucel, as a treatment for DLBCL and PMBCL.

                                                  Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study

                                                  by Zacks Equity Research

                                                  Lilly (LLY) posts positive top-line results from a second phase III study on Taltz for the treatment of Ankylosing Spondylitis (AS).